A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 82
- 主要终点
- Number of Participants With Primary Patency
研究概览
简要总结
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).
详细描述
A global, prospective, multicenter, 2:1 randomized trial evaluating the safety and effectiveness of the DES BTK Vascular Stent System compared to standard percutaneous transluminal angioplasty to treat infrapopliteal artery lesions in subjects with critical limb ischemia(CLI).
Approximately 201 subjects will be randomized/enrolled to support a 2:1 randomization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
A review of the wound assessment data will be completed by independent reviewer(s) who will be blinded to the randomized therapy.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is 18 years or older and has signed and dated the trial informed consent form (ICF)
- •Subject is willing and able to comply with the trial testing, procedures and follow-up schedule
- •Subject has chronic, symptomatic lower limb ischemia, determined by Rutherford categories 4 or 5 in the target limb, with wound(s) confined to toes/forefoot
- •Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator
- •Intra-procedure Inclusion Criteria:
- •Stenotic, restenotic or occlusive target lesion(s) located in the tibioperoneal trunk, anterior tibial, posterior tibial and/or peroneal artery(ies).
- •Target lesion(s) must be at least 4cm above the ankle joint
- •A single target lesion per vessel, in up to 2 vessels, in a single limb
- •Degree of stenosis ≥ 70% by visual angiographic assessment
- •Reference vessel diameter is between 2.5 - 3.25mm for phase A RCT
- •Total target lesion length (or series of lesion segments) to be treated is ≤ 70 mm for phase A RCT prior to the data monitoring committee's approval for stent overlap. (Note: Lesion segment(s) must be fully covered with one DES BTK stent, if randomized to stent)
- •Total target lesion length (or series of lesion segments) to be treated is ≤ 140 mm for phase A RCT after the data monitoring committee's approval for stent overlap (Note: Lesion segment(s) must be fully covered with up to two DES BTK stents, if randomized to stent)
- •Target vessel(s) reconstitute(s) at or above the stenting limit zone (4cm above the ankle joint)
- •Target lesion(s) is located in an area that may be stented without blocking access to patent main branches
- •Treatment of all above the knee inflow lesion(s) is successful prior to treatment of the target lesion
- •Guidewire has successfully crossed the target lesion(s)
排除标准
- •Life expectancy ≤ 1year
- •Stroke ≤ 90 days prior to the procedure date
- •Prior or planned major amputation in the target limb
- •Previous surgery in the target vessel(s) (including prior ipsilateral crural bypass)
- •Previously implanted stent in the target vessel(s)
- •Failed PTA of target lesion/vessel ≤ 60 days prior to the procedure date
- •Renal failure as measured by a GFR ≤ 30ml/min per 1.73m2, measured ≤ 30 days prior to the procedure date
- •Subject has a platelet count ≤ 50 or ≥ 600 X 103/µL ≤ 30 days prior to the procedure date
- •NYHA class IV heart failure
- •Subject has symptomatic coronary artery disease (ie, unstable angina)
- •History of myocardial infarction or thrombolysis ≤ 90 days prior to the procedure date
- •Non-atherosclerotic disease resulting in occlusion (eg, embolism, Buerger's disease, vasculitis)
- •Subject is currently taking Canagliflozin
- •Body Mass Index (BMI) <18
- •Active septicemia or bacteremia
- •Coagulation disorder, including hypercoagulability
- •Contraindication to anticoagulation or antiplatelet therapy
- •Known allergies to stent or stent components
- •Known allergy to contrast media that cannot be adequately pre-medicated prior to the interventional procedure
- •Known hypersensitivity to heparin
- •Subject is on a high dose of steroids or is on immunosuppressive therapy
- •Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)
- •Intra-procedure Exclusion Criteria
- •Angiographic evidence of intra-arterial acute/subacute thrombus or presence of atheroembolism
- •Treatment required in > 2 target vessels (Note: a target lesion originating in one vessel and extending into another vessel is considered 1 target vessel)
- •Treatment requires the use of alternate therapy in the target vessel(s)/lesion(s), (eg, atherectomy, cutting balloon, re-entry devices, laser, radiation therapy)
- •Aneurysm is present in the target vessel(s)
- •Extremely calcified lesions
结局指标
主要结局
Number of Participants With Primary Patency
时间窗: 12 months
Twelve-Month Primary Patency defined as a binary endpoint to be determined via duplex ultrasound (DUS) measuring flow at the 12-month follow-up visit, in the absence of clinically-driven target lesion revascularization (TLR) or bypass of the target lesion. Data table consists of the number of participants with flow as assessed by DUS.
Number of Participants Free From Major Adverse Events (MAE)
时间窗: 12 months
The primary safety endpoint assesses freedom from major adverse events (MAE) at 12 months post-procedure. (MAE is defined as: above ankle amputation in index limb; major re-intervention; and perioperative (30 day) mortality)
次要结局
未报告次要终点